Indications -- pain Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Indications -- pain

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: scaram(o)uche	2/4/2005 3:12:28 PM
	of 101

US FDA staff: Novartis drug risk similar to Vioxx Fri Feb 4, 2005 02:55 PM ET WASHINGTON, Feb 4 (Reuters) - U.S. regulatory staff said a Novartis AG (NOVN.VX: Quote, Profile, Research) trial showed the risk of heart attack, stroke and deaths in patients taking its experimental painkiller Prexige were similar to Merck & Co. Inc.'s (MRK.N: Quote, Profile, Research) now withdrawn Vioxx, documents released on Friday showed. Prexige, which is not yet approved in the United States, showed greater cardiovascular risks compared to naproxen but similar risks compared to ibuprofen, the reviewers said. The trial also showed Prexige had offered an "advantage" over other pain drugs that can cause stomach problems.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next